Drug intelligence / Profile preview

URG-301

Development stage: Unknown
Lead developer: Urigen Pharmaceuticals
Modality: Small Molecules
Administration: Intraurethral

Overview

URG-301 is an intraurethral lidocaine suppository developed for the treatment of urological pain. Urigen Pharmaceuticals, which was developing the drug, returned all development and commercialization rights for URG-301 to Kalium Inc. by mutual agreement, allowing Urigen to focus its resources on its lead asset, URG101.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on URG-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on URG-301.

Explore the full profile